Are Virtual SIVs the Future?: Interview with Jennifer Brandl
10/28/21 • 24 min
Jennifer Brandl is the Associate Director of Clinical Operations at Kezar Life Sciences. She has 15 years of experience as a researcher and clinical operations specialist, and she is currently pursuing a Master’s degree in Data Science from the University of Wisconsin.
Jennifer credits her prior experience at a smaller biotech company with giving her a critical foundation in clinical conduct and study execution. At Kezar, she leverages this expertise and her passion for research to support the company’s development of pioneering therapies and to change the lives of patients.
Episode Highlights
- The elements of Jennifer’s expertise that have especially helped her drive success in the trials she manages
- The benefits of functional service provider outsourcing models
- How Kezar’s patient-centric nature had the company well prepared to navigate the COVID-19 pandemic
- The greatest challenges Jennifer and Kezar experienced due to the pandemic, and some positive outcomes
- Important considerations for organizations exploring home health options
- How communication and relationship-building form the foundation of clinical trial work
- The challenges and benefits she’s experienced conducting site initiation visits virtually
- How best to prepare before updating or transforming site initiation processes
- What she believes is next for decentralized clinical trials
- How automation and tech adoption can help extract more insight from data
Resources:
Kezar Life Sciences
Jennifer Brandl on LinkedIn
Conversations in Clinical Trial Readiness Interview Series
Jennifer Brandl is the Associate Director of Clinical Operations at Kezar Life Sciences. She has 15 years of experience as a researcher and clinical operations specialist, and she is currently pursuing a Master’s degree in Data Science from the University of Wisconsin.
Jennifer credits her prior experience at a smaller biotech company with giving her a critical foundation in clinical conduct and study execution. At Kezar, she leverages this expertise and her passion for research to support the company’s development of pioneering therapies and to change the lives of patients.
Episode Highlights
- The elements of Jennifer’s expertise that have especially helped her drive success in the trials she manages
- The benefits of functional service provider outsourcing models
- How Kezar’s patient-centric nature had the company well prepared to navigate the COVID-19 pandemic
- The greatest challenges Jennifer and Kezar experienced due to the pandemic, and some positive outcomes
- Important considerations for organizations exploring home health options
- How communication and relationship-building form the foundation of clinical trial work
- The challenges and benefits she’s experienced conducting site initiation visits virtually
- How best to prepare before updating or transforming site initiation processes
- What she believes is next for decentralized clinical trials
- How automation and tech adoption can help extract more insight from data
Resources:
Kezar Life Sciences
Jennifer Brandl on LinkedIn
Conversations in Clinical Trial Readiness Interview Series
Previous Episode
Why every clinical trial needs to consider Middle East and African sites: Interview with Ahmed Hamouda
Ahmed Hamouda
Ahmed Hamouda is the Head of Clinical Operations in the Middle East and Africa at RAY. In more than 10 years in the clinical research field, Ahmed has worked on both the CRO side and the pharmaceutical side in Europe, the Middle East, the Far East, and Africa.
Ahmed brings the full range of his experience to bear at RAY, which provides outsourcing and consulting services to support pharmaceutical and biotech companies through the clinical trial development process. With RAY, Ahmed leverages his expertise to bring hope and opportunity to patient populations who would not otherwise be reached.
Episode Highlights
- Why Africa and Middle Eastern markets represent a major opportunity for sponsors
- What regulations and unique requirements sponsors need to understand before moving into these markets
- How the site selection and preparation process is different in these markets as opposed to in the U.S.
- The importance of partnering with qualified regional experts
- The challenges involved in driving patient participation in these regions
- How one rare disease clinical trial was saved by a move from the U.S. to the Middle East, and how that move paid off in terms of recruitment
- Potential logistical issues with global trials and how RAY manages them
- Why continuous education is so important for sites
- How Ahmed and RAY estimate the timeframe for study startup in a new region
- The unexpected positive regional outcomes of the pandemic
Resources:
Ray-CRO
Ahmed Hamouda on LinkedIn
Conversations in Clinical Trial Readiness Interview Series
Next Episode
Pandemic Impact on Clinical Trial Recruitment with Atul Mahableshwarkar, M.D., DFAPA
Atul Mahableshwarkar
Dr. Atul Mahableshwarkar is the Senior Vice President of Drug Development at Emalex Biosciences. He is a trained psychiatrist who began his career in clinical practice and academia. Since joining the pharmaceutical industry, he has had the opportunity to learn from both successes and failures in his clinical trial work at companies of all sizes.
Atul shares that early in his career, he was more interested in research than methodology. He credits his colleagues at the time with opening his eyes to the fact that incorrect operations can sink an otherwise viable product. The interest in methodology that that understanding sparked has shaped his career over the last 15-20 years.
Episode Highlights
- The pivotal role of strong methodology in allowing good products to succeed
- Atul’s advice for others beginning to design clinical trials
- What he sees as the greatest challenges clinical trials have in common
- How teams can help motivate clinical trial participation
- Where standard concepts of patient-centricity may be lacking
- How collaboration can help minimize mistakes
- The Orphan Drug and Fast Track designations Emalex has earned from the FDA, and how other organizations can pursue Orphan Drug status
- How the pandemic nearly tripled Emalex’s enrollment
- The importance of supporting sites that may feel threatened by decentralized clinical trials
- The pandemic-enforced recruitment practices he plans to continue
- Key considerations in choosing a preferred ratings scale, and what his is
- Rater training as a misnomer that needs revising
- How to assess and manage raters appropriately
- The value of monitoring data and communicating insights to stakeholders in real time
Links
https://www.linkedin.com/in/atul-mahableshwarkar-07772338/
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/conversations-in-clinical-trial-readiness-530683/are-virtual-sivs-the-future-interview-with-jennifer-brandl-68754957"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to are virtual sivs the future?: interview with jennifer brandl on goodpods" style="width: 225px" /> </a>
Copy